-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $54

Benzinga·05/13/2026 13:26:56
Listen to the news
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $38 to $54.